I Watched Roughly 125 Deals Fail the Same Way. It Was Almost Never Management.
Between nine and eighteen months into the hold, PE Boards routinely become exasperated, frustrated, and disappointed. Execution drifts. The numbers slip. The CEO can explain each miss, but rarely into a coherent story. The board deck adds new initiatives faster than old ones close. By the third meeting where someone uses the phrase “execution issue,” most deal partners have privately concluded that the management team is the problem.
Three uncomfortable options. Replace the CEO and reset the clock. Keep the CEO and hope. Write the deal down. None is a solution.
There is a fourth option, and it is the one I want to argue for in this piece.
In 25 years of thesis testing, commercial diligence, and sell-side market studies – the work that shapes IC memos before they’re written — I calculate that I have worked on about 400 deals. Through that work and in my work leading TheOperators.pe community over the last couple of years, one failure pattern has emerged often. I stopped attributing it to management.
The pattern is this: the investment thesis that the deal team underwrote is rarely translated to the people responsible for delivering against it. In some cases, not even the value creation plan. The deliberate, sustained reluctance to hand off the context, the “Why We Did This Deal” perspective is crippling because it prevents management from thinking like an owner, understanding intent, understanding opportunities seen, threats uncovered (and mitigants identified).
Translation is what the deal team owes management. Most deal teams treat it as finished work when it is, in fact, unfinished. The cost of that unfinished work is roughly 40% of deals failing to meet underwriting expectations.
The standard explanation is that failure is on management. The honest explanation points earlier.
This is the execution gap. And mistaking it for a personnel problem may be the most expensive blind spot in private equity.
The reframe most deal teams have never been offered.
PE reporting is fairly well buttoned up. Almost every PE-backed company has a dashboard. KPIs, trending charts, variance reports, a board deck refreshed quarterly. Some have invested in real reporting infrastructure — Anaplan, Adaptive, Power BI. The dashboards are not the problem.
The problem is that dashboards measure performance. They do not produce it. While reporting standards in PE are healthy, PE operating systems shared between Management, Operating Teams and Deal Teams are almost nonexistent.
This is the difference between looking in the rear-view mirror and driving the car. A dashboard tells you revenue is 8% below plan. An operating system determines who owns the gap, what caused it, which assumptions are no longer true, what decision must be made next, by whom, by when, and how progress will be tracked between now and the next QBR. Most portfolio companies have invested heavily in the first capability and barely at all in the second. That is the gap most deal teams have spent their hold periods unknowingly funding.
Reporting infrastructure is not execution discipline. They are different categories of capability. The first looks backward at outcomes; the second looks forward at decisions. Companies that confuse the two end up with very clean dashboards and very stalled value creation plans — which is precisely the pattern that I have seen for years.
The operating system most PE-backed companies need has a specific shape. It is not EOS, which was built for entrepreneur-owned businesses without a sponsor in the cap table. It is not Scaling Up, which assumes the company is in growth mode rather than thesis-execution mode. It is not the management consultancy’s 100-day playbook, which is a project plan rather than an operating system. What PE-backed companies need is a framework purpose-built for the specific transition the company is in: from acquired asset to value-creating enterprise to exit-ready business — typically in five to seven years, with a defined investment thesis as the target. In other words, customized for each portfolio company, but with common language and structure across the portfolio.
I have spent the last two years building that framework with a community of more than 50 PE operating partners and the CXOs who run their portfolio companies. We call it the Value Creation Operating System. It rests on five pillars, each of which addresses a specific category of risk that emerges in PE-backed companies between acquisition and exit.
If the management team is not the problem — or not the whole problem — those five risks are where the problem actually lives.
Five risks. Three live before execution begins. Two live during it.
The risks are not equal, and they do not all happen at the same time. Three of them sit in what I call the strategic translation layer — the space between the deal team’s investment thesis and the management team’s operating reality. The other two sit in the organizational execution layer — the space between the management team’s operating reality and what the company actually delivers. Most deal teams diagnose problems in the second layer when the failure is almost always upstream, in the first.
The Three Strategic Translation Risks.
Alignment Risk is the probability that the board, the operating partner, the CEO, and the leadership team are operating from different assumptions about what creates value, what destroys it, and what success looks like at exit. Alignment is not agreement — leadership teams can be aligned and still disagree on tactics. Alignment is shared understanding of the underwriting logic. When it is missing, the leadership team looks busy but pulls in directions the deal team cannot reconcile. The symptom you have seen: the CEO and the CFO give two different answers to the same board question, and neither is wrong.
Governance Risk is the probability that unclear decision rights, escalation paths, or board-management interactions impair execution. The diligence process produces an investment committee memo with a clear authority structure. By month nine of the hold, that structure has been quietly renegotiated through a dozen small concessions that nobody documented. The symptom: decisions stall because three people each believe one of the other two should be making them. The deal partner finds themselves making operating decisions because no one else will.
Deployment Risk is the probability that strategic intent, priorities, and value creation initiatives never reach Tier 2 and Tier 3 leaders in a form they can act on. The board understands the priorities. The CEO understands the priorities. The Regional Sales Manager and the Plant Manager do not — or they understand a degraded version that was diluted three handoffs ago. This is the risk most PE frameworks ignore entirely, and in my experience the one that quietly kills more value creation plans than any other.
The Two Organizational Execution Risks
Accountability Risk is the probability that initiatives, commitments, and priorities fail to translate into measurable outcomes due to weak ownership, follow-through, or consequence management. The symptom is the QBR where the same three initiatives are reported as “on track” three quarters in a row, with no underlying progress to point to. Activity is not accountability. Progress is not accountability. Named ownership of specific commitments, reviewed against specific dates, is accountability.
Transformation Risk is the probability that leadership behaviors, organizational capabilities, talent, or operating practices fail to evolve at the speed the investment thesis requires. The company that was acquired is not the company that must exist at exit. If the leadership team is running the same operating cadence in year three that it ran in year one, the deal is likely already failing, even if the numbers have not yet shown it.
Each of these five risks is separately diagnosable. That is the point. The diagnosis that management is the problem collapses five different failure modes into one undifferentiated verdict, which is why it produces a binary response (replace or write down). Diagnosing which of the five risks is most concerning produces a different set of options — most of which do not require firing the CEO.
The diagnostic that came out of all this.
The five risks I’ve described are not categories I invented in a vacuum. They emerged from the same pattern-recognition work the article is built on — what does the failure actually look like when you watch enough deals fail the same way?
Once the architecture became clear, the next question was practical. If alignment risk, governance risk and deployment risk are separately diagnosable, what would a leadership team actually need to answer to know which one is most elevated in their company? Not what the CEO believes. Not what the operating partner suspects. What the underlying conditions in the company would reveal if you asked the right questions.
We built that diagnostic. It is fifteen questions, three per risk domain, plus one final question I will come to in a moment. It takes a senior operator about eight minutes to complete. It produces five risk scores and one composite confidence score, and a report that points to where the company is quietly vulnerable.
The final question is the one I would ask a CEO if I could only ask one. “If you were investing your own capital, how confident would you be in this organization’s ability to execute its Value Creation Plan over the next 24 months?” Most CEOs cannot answer that question honestly in the moment. The diagnostic gives them a way to surface the answer indirectly — through the other 15 questions, and the resulting five domain scores that, taken together, tell the story their gut already knows.
The diagnostic is free. It is not a sales tool. It is a tool I built because, after 25 years of watching the same failure pattern repeat, I wanted to give deal teams and management teams a way to see the failure earlier — before the trilemma sets in, before the CEO conversation goes badly, before the deal is written down.
For a deal partner reading this article: the most useful thing you can do with the diagnostic is not take it yourself. You can do so, but I also encourage you to send it to a CEO whose company is not delivering against the thesis, with a note that says “I’d like to have a different conversation at the next QBR. Take this first.”
Every diagnostic completed becomes part of what will eventually be the first proprietary execution-risk benchmark in middle-market PE. The respondents contributing now are building the comparative dataset their successors will use to interpret their own scores.
What I would ask you to do.
If you are a deal partner who has read this far, you have a portfolio. You have at least one company in it that is not where you thought it would be at this point in the hold. The trilemma may already be forming in your head.
Before it does, take eight minutes and send the diagnostic to the CEO of that company. Tell her you want to have a different conversation at the next QBR. Let the report come back. Sit with the five risk scores and the confidence number. Then decide whether the problem is management, or the problem is something the deal team and the CEO can solve together.
If the answer turns out to be the latter, you have just saved yourself a CEO search, a reset year, and the part of the IC conversation you were dreading.
The diagnostic lives here. Friday’s workshop covers it in depth.